Impact of gene polymorphisms in drug‐metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation
- 12 September 2020
- journal article
- research article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 128 (2) , 297-304
Abstract
Rivaroxaban is excreted from the body via multiple pathways involving glomerular filtration, drug‐metabolizing enzymes and transporters. In this study, we aimed to examine the impact of single nucleotide polymorphisms in P‐glycoprotein, breast cancer resistance protein, cytochrome P450 (CYP) 3A5 and CYP2J2 on the pharmacokinetics of rivaroxaban. Eighty‐six patients with non‐valvular atrial fibrillation (NVAF) undergoing AF catheter ablation were enrolled in this study. In these analyses, the dose‐adjusted plasma trough concentration ratio (C0h/D) of rivaroxaban was used as the pharmacokinetic index. The median (quartile range) rivaroxaban C0h/D was 3.39 (2.08‐5.21) ng/mL/mg (coefficient of variation: 80.5%). The C0h/D did not differ significantly among ABCB1 c.3435C>T, c.2677G>A/T, c.1236C>T, ABCG2 c.421C>A, CYP3A5*3 and CYP2J2*7 genotypes. Stepwise selection multiple linear regression analysis showed that the estimated glomerular filtration rate was the only independent factor influencing the C0h/D of rivaroxaban (R2 = 0.152, P < 0.001). There was a significant correlation between the C0h of rivaroxaban and prothrombin time (PT) (rho = 0.357, P = 0.001). In patients with NVAF, pharmacokinetic genotype tests are unlikely to be useful for prediction of the C0h of rivaroxaban.Keywords
This publication has 36 references indexed in Scilit:
- Clinical Pharmacokinetic and Pharmacodynamic Profile of RivaroxabanClinical Pharmacokinetics, 2013
- Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjectsBritish Journal of Clinical Pharmacology, 2013
- Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillationThe Lancet Neurology, 2012
- Pharmacogenetic biomarkers: cytochrome P450 3A5Clinica Chimica Acta, 2012
- Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromesBritish Journal of Clinical Pharmacology, 2012
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitorBritish Journal of Clinical Pharmacology, 2010
- Revised Equations for Estimated GFR From Serum Creatinine in JapanAmerican Journal of Kidney Diseases, 2009
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976
- CLINICAL CALORIMETRYArchives of internal medicine (1908), 1916